Immatics N.V. (IMTX) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prime Medicine (PRME) has outperformed Immatics N.V. (IMTX) over the past year, losing 2.2% versus a loss of 43.4%. Immatics N.V. is the larger company by market cap ($878.6 million vs $791.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | PRME |
|---|---|---|
| Share price | $5.77 | $3.55 |
| Market cap | $878.58M | $791.62M |
| 1-day change | -3.03% | -7.55% |
| YTD return | -45.05% | +2.31% |
| 1-year return | -43.43% | -2.20% |
| 5-year return | -48.57% | — |
| EPS (TTM) | $-1.95 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.63M |
| Revenue growth (YoY) | — | +55.28% |
| Net income (latest FY) | — | $-201.14M |
| Operating margin | — | -4498.06% |
| Net margin | — | -4342.44% |
| 52-week high | $12.41 | $5.91 |
| 52-week low | $5.72 | $2.67 |
| Distance from 52-week high | -53.51% | -39.93% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +176.78% | +108.17% |
| Average volume | 962.74K | 4.64M |
| Shares outstanding | 152.27M | 222.99M |
| Employees | 721 | 146 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRME has outperformed IMTX by 41.2 percentage points over the past year.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
IMTX vs PRME FAQ
Which is bigger, Immatics N.V. or Prime Medicine?
Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $791.62M for Prime Medicine (PRME).
Which stock has performed better over the past year, IMTX or PRME?
PRME returned -2.20% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.